Our understanding of the molecular pathogenesis of myeloid malignancies relies largely on the knowledge of cytogenetic abnormalities and recurrent chromosomal translocations, many of which have been successfully modeled in laboratory animals.
Based on our improving knowledge of cellular abnormalities in lupus, a variety of T-cell and B-cell surface-expressed molecules can conceptually be targeted to bypass or correct these dysfunctions.
Our knowledge of cardiovascular abnormalities in PHPT is mostly based on data from cohorts that include patients with pre-existing cardiovascular risk factors or diseases that may confound the results.
As knowledge of the molecular abnormalities and dysregulated cellular processes contributing to the pathogenesis and progression of lung cancer has been acquired, intense interest has been directed at developing agents that target these abnormalities.
Knowledge of the genetic abnormalities present in pediatric LGAs is limited, though recent studies have identified BRAF translocations, chromosomal duplications, and occasional base mutations in low-grade astrocytomas[18], [25], as well as diverse mechanisms for activating the ERK/MAPK pathway in pilocytic astrocytomas [23].
Current therapeutic approaches for the management of patients with metastatic RCC utilize knowledge of histology, molecular abnormalities, clinical prognostic factors, the natural history of this malignancy, and the treatment efficacy and toxicity of available agents.
This review will summarize our knowledge of somatic chromosome abnormalities and their effects on sperm, susceptibility to sperm chromosome anomalies in chromosomally normal infertile men, and meiotic errors in translocation carriers and infertile men with a normal chromosome constitution.
Blood was drawn from women with a suspect initial mammogram, prior to any knowledge of whether the abnormality observed during first screening was benign or malignant.
The expanding knowledge of the underlying molecular abnormalities in this once very poorly understood cancer should allow for increasingly rational clinical trial design and improved patient outcomes.
